Haisco Pharmaceutical Group9(A chinese modern pharmaceutical group with new drug research and development being its core) announced on October 11th night that its wholly owned subsidiary, Sichuan Haisco, recently received notice from State Food and Drug Administration, informing that the HSK3486 emulsion injection which has been checked in August 2020 meet the requirements of drug registration, and has been agreed to be done to “maintain general anesthesia” Ⅲ phase of clinical trials. HSK3486 is a brand new intravenous anesthetic drug developed by the company with independent intellectual property rights. It is intended to be used for indications such as induction of general anesthesia in surgery, sedation/anesthesia for endoscopic diagnosis and treatment, and sedation in ICU and etc.
